SCHEDULE: Dr. Dalia Megiddo Boosts Stake in Nasus Pharma to 20.9%

Dr. Dalia Megiddo has reported beneficial ownership of 20.9% of Nasus Pharma Ltd.'s ordinary shares as of September 30, 2025.

Summary

• Dr. Dalia Megiddo, a citizen of Israel, has filed a Schedule 13G with the SEC.
• She beneficially owns 1,888,873 ordinary shares of Nasus Pharma Ltd.
• This ownership represents 20.9% of the issuer's ordinary shares outstanding.
• The percentage is calculated based on 9,014,105 ordinary shares that Nasus Pharma Ltd. advised were issued and outstanding as of September 30, 2025.
• Dr. Megiddo holds sole voting power and sole dispositive power over all 1,888,873 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant insider stake, which is generally viewed positively as it suggests strong alignment of interests and confidence from a key individual. No negative information is present.

Positives

• A significant insider, Dr. Dalia Megiddo, holds a substantial 20.9% stake in Nasus Pharma Ltd., indicating strong alignment with shareholder interests.
• The reporting person has sole voting and dispositive power over her shares, suggesting direct control over her investment.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance.

Industry Context

A Schedule 13G filing indicates a significant passive ownership stake by an individual or entity. For Nasus Pharma Ltd., a pharmaceutical company, a substantial insider stake by Dr. Dalia Megiddo could be viewed positively by the market, suggesting confidence in the company's future, especially if she is a key executive or founder. This type of filing is common across all industries when an investor crosses the 5% beneficial ownership threshold.

Comparison to Industry Standards

• An insider holding over 20% of a company's shares is a substantial stake, often seen as a positive indicator of alignment between management/insiders and shareholder interests, exceeding typical institutional investor stakes which are often below 10% for passive filings.
• Compared to other biotech or pharma companies, a 20.9% insider stake is significant and can be interpreted as a strong vote of confidence in the company's drug pipeline or strategic direction, potentially higher than average for companies of similar market capitalization where institutional ownership might be more fragmented.

Stakeholder Impact

• Shareholders: The significant insider ownership by Dr. Dalia Megiddo may instill confidence, suggesting strong alignment of interests between a key individual and other shareholders.

Key Dates

Recommendation

The filing indicates a substantial 20.9% beneficial ownership by Dr. Dalia Megiddo, a significant insider. While a large insider stake is generally a positive signal, suggesting confidence and alignment of interests, this Schedule 13G filing does not provide financial performance data, strategic updates, or other comprehensive information typically required for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive insider sentiment while awaiting further operational and financial disclosures.

Keywords

Nasus Pharma Ltd., Dr. Dalia Megiddo, Schedule 13G, Beneficial Ownership, Ordinary Shares, Insider Ownership, M7071P109